Molbio Diagnostics IPO: Overview
Molbio Diagnostics Limited, a Goa-headquartered point-of-care (POC) molecular diagnostics company, is set to launch its ₹939.70 crore mainboard IPO on August 10, 2026. The issue closes on August 12, 2026, with listing on both BSE and NSE expected on August 17, 2026.
The issue combines a fresh issue of ~₹200 crores with a sizeable offer for sale of up to 91,66,000 equity shares by existing shareholders.
Molbio Diagnostics IPO: Key Dates
|
Event |
Date |
|
Anchor Bidding Date |
August 7, 2026 |
|
IPO Open Date |
August 10, 2026 |
|
IPO Close Date |
August 12, 2026 |
|
Basis of Allotment |
August 13, 2026 |
|
Refunds Initiated |
August 14, 2026 |
|
Credit to Demat Account |
August 14, 2026 |
|
Listing Date (BSE, NSE) |
August 17, 2026 |
Molbio Diagnostics IPO: Issue Details
|
Particular |
Detail |
|
Face Value |
₹1 per equity share |
|
Price Band |
₹768 to ₹807 per share |
|
Total Issue Size |
~₹939.70 crores |
|
Fresh Issue |
~₹200 crores |
|
Offer for Sale |
Up to 91,66,000 equity shares |
|
Issue Type |
Book Building Issue |
|
Listing |
BSE, NSE |
Reservation is split 35% for retail, 50% for QIB, and 15% for NII/HNI.
Molbio Diagnostics IPO: Lot Size
|
Application |
Lots |
Shares |
Amount |
|
Retail (Minimum) |
1 |
18 |
₹14,526 |
|
Retail (Maximum) |
13 |
234 |
₹1,88,838 |
|
S-HNI (Minimum) |
14 |
252 |
₹2,03,364 |
|
S-HNI (Maximum) |
68 |
1,224 |
₹9,87,768 |
|
B-HNI (Minimum) |
69 |
1,242 |
₹10,02,294 |
About Molbio Diagnostics
Incorporated in October 2000 and headquartered in Verna, South Goa, Molbio Diagnostics is a global point-of-care molecular diagnostics company engaged in the research, development, manufacturing, and commercialisation of rapid diagnostic solutions for infectious and non-communicable diseases.
Its flagship offering is the Truenat platform — a portable molecular diagnostics system comprising the Trueprep nucleic acid extraction device, Truelab real-time PCR analysers, and disease-specific Truenat test kits. As of March 31, 2026, the company offered molecular testing for 30 diseases through 43 assays, including tuberculosis, COVID-19, hepatitis B and C, HIV, and HPV. Its installed manufacturing capacity stood at 5,400 devices per annum and 3.90 crore Truenat test kits per annum, with FY26 sales of 2,524 Truenat devices alongside a substantial volume of test kits. As of May 31, 2026, the company carried consolidated outstanding borrowings of ₹422.50 crore.
Objects of the Issue
|
Purpose |
Amount |
|
Capital expenditure for setting up R&D facility, Centre of Excellence, and connected office space |
₹118.08 crores |
|
Capital expenditure for plant, machinery, and equipment at Goa Unit I, Goa Unit II, and Visakhapatnam Unit |
₹79.04 crores |
|
General corporate purposes |
Balance amount |
Financial Performance
|
Period |
Revenue |
Expense |
PAT |
Assets |
|
FY2024 |
₹840.66 Cr |
₹657.83 Cr |
₹83.54 Cr |
₹1,221.06 Cr |
|
FY2025 |
₹1,027.94 Cr |
₹820.41 Cr |
₹138.58 Cr |
₹1,461.56 Cr |
|
FY2026 |
₹1,455.17 Cr |
₹1,221.35 Cr |
₹164.14 Cr |
₹2,148.42 Cr |
Both revenue and profit have grown consistently across all three years, with revenue up roughly 73% and PAT up nearly 97% from FY24 to FY26 — a strong growth trajectory for a diagnostics company of this scale.
Key Valuation Metrics (FY2026)
|
KPI |
Value |
|
ROE |
15.59% |
|
ROCE |
17.55% |
|
EBITDA Margin |
22.56% |
|
PAT Margin |
11.28% |
|
Basic EPS |
₹14.77 |
|
RoNW |
14.55% |
|
Net Asset Value (NAV) |
₹101.51 |
Peer Comparison
|
Company |
EPS |
P/E Ratio |
RoNW |
NAV |
Income |
|
Poly Medicure Limited |
31.79 |
52.61 |
10.37% |
306.45 |
₹1,875.26 Cr |
|
Dr. Lal Pathlabs Limited |
30.24 |
62.20 |
20.78% |
145.00 |
₹2,762.91 Cr |
|
Metropolis Healthcare Limited |
9.19 |
63.72 |
12.56% |
72.98 |
₹1,645.85 Cr |
|
Vijaya Diagnostics Centre Limited |
16.81 |
81.02 |
18.07% |
93.02 |
₹814.20 Cr |
Molbio's own P/E isn't disclosed as "N/A" in the offer document. It's worth noting these listed peers are diagnostic services/lab chains and medical device makers rather than direct point-of-care molecular diagnostics comparables — Molbio's own business model (device + consumable/test-kit sales) differs meaningfully from the lab-services model of Dr. Lal Pathlabs, Metropolis, and Vijaya Diagnostics.
Promoter Holding
|
Particular |
Pre-Issue Shares |
Pre-Issue % |
Post-Issue Shares |
Post-Issue % |
|
Promoter & Promoter Group |
5,25,97,450 |
46.65% |
4,34,31,450 |
37.69% |
|
Others |
Open A Free Demat Account Today Get StartedBSE Saatvik 100 Index  07 Jul 2026 EPFO 8.25% Interest Rate for FY26 Confirmed by Government 18 Jun 2026 Section 87A Rebate vs Capital Gains Tax 15 Jun 2026 EPFO 3.0 - New Rule to Withdraw Money via UPI & ATM 08 Apr 2026 ELSS vs ULIP: Which Tax-Saving Option Should You Choose? 02 Jan 2026 HNI vs Retail IPO: Where Do You Actually Stand a Chance? 06 Dec 2025 |